Abstract
Background: Lymphomatoid papulosis (LyP) is a clonal T cell proliferation with large cell histology, a chronic course, and an increased risk of lymphoma. Bexarotene (Targretin®) is an RXR-selective retinoid (rexinoid) approved for the cutaneous manifestations of cutaneous T cell lymphoma. Objective: To determine whether bexarotene is effective in treating LyP. Methods: Ten patients with chronic and symptomatic LyP were prospectively treated with oral (n =3) or topical gel (n =7) formulations of bexarotene. Results: A favorable response to bexarotene treatment with decreased numbers or duration of lesions was seen in all with objective responses in 8 patients. Conclusions: Bexarotene may be an effective palliative treatment for LyP, warranting further controlled studies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 142-147 |
| Number of pages | 6 |
| Journal | Dermatology |
| Volume | 206 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2003 |
Keywords
- Anaplastic CD30+T cell lymphoma
- Cutaneous T-cell lymphoma
- Lymphomatoid papulosis
- Lymphoproliferative disorder
- Retinoids
- Targretin®
ASJC Scopus subject areas
- Dermatology
Fingerprint
Dive into the research topics of 'Bexarotene is a new treatment option for lymphomatoid papulosis'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS